Clinical trial · Interventional
Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients
NCT01718613CI-TRIAL-00033006VANCS IIcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although arginine vasopressin has been used as an additional drug in refractory shock in worldwide clinical practice, there are no prospective studies using it as a first choice therapy in patients with cancer and septic shock. The aim of this study is assess if the use of arginine vasopressin would be more effective on treatment of septic shock in cancer patients than norepinephrine, decreasing the composite end point of mortality and organ failure in 28 days.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Septic Shock | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Norepinephrine | Drug | — | UNRESOLVED |
| Vasopressin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Norepinephrine
- interventionNames
- Drug: Norepinephrine
- type
- ACTIVE_COMPARATOR
- label
- Vasopressin
- interventionNames
- Drug: Vasopressin
Primary outcomes (1)
- measure
- 28-day mortality
- timeFrame
- 28-day from randomization
- description
- Mortality from all causes in 28-day follow-up
Secondary outcomes (6)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Solid neoplasm needing ICU * Septic Shock according standard criteria Exclusion Criteria: * Younger than 18 years; * Pregnancy; * Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis; * Severe hyponatremia (Na\<130mEq/L); * Acute mesenteric ischemia; * Acute myocardial infarction; * Cardiogenic shock; * Current use of vasopressor before randomization * Expected ICU stay less than 24 hours * Enrolled in another study; * Refusal to consent.
References
Publications (1)
- DERIVEDHajjar LA, Zambolim C, Belletti A, de Almeida JP, Gordon AC, Oliveira G, Park CHL, Fukushima JT, Rizk SI, Szeles TF, Dos Santos Neto NC, Filho RK, Galas FRBG, Landoni G. Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial. Crit Care Med. 2019 Dec;47(12):1743-1750. doi: 10.1097/CCM.0000000000004023. PMID 31609774